William E. Truog

William E. Truog

Auto-generated profile, based on publicly available information

William E. Truog

School of Medicine, University of Missouri-Kansas City, 2411 Holmes Street, Kansas City, MO 64108, USA; Division of Neonatology, Department of Pediatrics, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA; Center for Infant Pulmonary Disorders, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SDSara B. DeMauro
Sara B. DeMauro
JDJo Ann D'AGostino
Jo Ann D'AGostino
CBCarla M Bann
Carla M Bann
JBJudy Bernbaum
Judy Bernbaum
MGMarsha Gerdes
Marsha Gerdes
HKHaresh Kirpalani
Haresh Kirpalani

1 September 2019 in Early Human Development
Verified
Journal Article
Closed access
ALAlaina Linafelter
Alaina Linafelter
ACAlain Cuna
Alain Cuna
CLCynthia Liu
Cynthia Liu
AQAnastasia Quigley
Anastasia Quigley
WTWilliam E. Truog
William E. Truog
AOAlexandra Oschman
Alexandra Oschman

1 July 2008 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
WTWilliam E Truog
William E Truog
DXDong Xu
Dong Xu
IEIkechukwu I Ekekezie
Ikechukwu I Ekekezie
SMSherry Mabry
Sherry Mabry
MRMo Rezaiekhaligh
Mo Rezaiekhaligh
MSMichael J Soares
Michael J Soares

5 June 2014 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
WTW E Truog
W E Truog
LNL D Nelin
L D Nelin
ADA Das
A Das
DKD E Kendrick
D E Kendrick
EBE F Bell
E F Bell
TNthe NICHD Neonatal Research Network
the NICHD Neonatal Research Network
Objective: The use of inhaled nitric oxide (iNO) in preterm infants remains controversial. In October 2010, a National Institutes of Health consensus development conference cautioned against use of iNO in preterm infants. This study aims (1) to determine the prevalence and variability in use of iNO in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN) before and after the consensus conference and (2) separately, to examine associations between iNO use and severe bronchopulmonary dysplasia (BPD) or death. Study design: The NICHD NRN Generic Database collects data including iNO use on very preterm infants. A total of 13 centers contributed data across the time period 2008 to 2011. Infants exposed or not to iNO were compared using logistic regression, which included factors related to risk as well as their likelihood of being exposed to iNO. Result: A total of 4885 infants were assessed between 2008 and 2011; 128 (2.6%) received iNO before day 7, 140 (2.9%) between day 7 and 28, and 47 (1.0%) at >28 days. Center-specific iNO use during 2008 to 2010 ranged from 21.9 to 0.4%; 12 of 13 sites reduced usage and overall NRN iNO usage decreased from 4.6 to 1.6% (P<0.001) in 2011. The use of iNO started between day 7 and day 14 was more prevalent among younger infants with more severe courses in week 1 and associated with increased risk of severe BPD or death (odds ratio 2.24; 95% confidence interval 1.23 to 4.07). Conclusion: The variability and total use of iNO decreased in 2011 compared with 2008 to 2010. iNO administration started at ⩾day 7 was associated with more severe outcomes compared with infants without iNO exposure.

1 April 2007 in Pediatrics
Verified
Journal Article
Closed access
PDF file
WTWilliam E. Truog
William E. Truog
PBPhilip L. Ballard
Philip L. Ballard
MNMichael Norberg
Michael Norberg
SGSergio Golombek
Sergio Golombek
RSRashmin C. Savani
Rashmin C. Savani
TIthe Nitric Oxide (to Prevent) Chronic Lung Disease Study Investigators
the Nitric Oxide (to Prevent) Chronic Lung Disease Study Investigators
OBJECTIVE. We compared serial measurements of inflammatory mediators and markers in infants treated with inhaled nitric oxide or placebo to assess the effects of inhaled nitric oxide therapy on lung inflammation during bronchopulmonary dysplasia. We investigated relationships between respiratory severity scores and airway concentrations of inflammatory markers/mediators.METHODS. As part of the Nitric Oxide (to Prevent) Chronic Lung Disease trial, a subset of 99 infants (52 placebo-treated infants and 47 inhaled nitric oxide-treated infants; well matched at baseline) had tracheal aspirate fluid collected at baseline, at 2 to 4 days, and then weekly while still intubated during study gas treatment (minimum of 24 days). Fluid was assessed for interleukin-1β, interleukin-8, transforming growth factor-β, N-acetylglucosaminidase, 8-epi-prostaglandin F2α, and hyaluronan. Results were normalized to total protein and secretory component of immunoglobulin A.RESULTS. At baseline, there was substantial variability of each measured substance and no correlation between tracheal aspirate fluid levels of any substance and respiratory severity scores. Inhaled nitric oxide administration did not result in any time-matched significant change for any of the analytes, compared with the placebo-treated group. There was no correlation between any of the measured markers/mediators and respiratory severity scores throughout the 24 days of study gas administration. In the posthoc analysis of data for inhaled nitric oxide-treated infants, there was a difference at baseline in 8-epi-prostaglandin F2α levels for infants who did (n = 21) and did not (n = 26) develop bronchopulmonary dysplasia at postmenstrual age of 36 weeks.CONCLUSIONS. Inhaled nitric oxide, as administered in this study, seemed to be safe. Its use was not associated with any increase in airway inflammatory substances.

1 January 1997 in Neonatology
Verified
Journal Article
Closed access
PDF file
WTWilliam E. Truog
William E. Truog
MNMichael Norberg
Michael Norberg
DTDonald W. Thibeault
Donald W. Thibeault
Non-cyclooxygenase-derived prostaglandin F2- (PGF2)-like compounds can be formed by membrane lipid peroxidation. We sought to characterize one member of this class of compounds, 8-epi-PGF2α, for its biological properties on the pulmonary vasculature in young piglets. We first compared 8-epi-PGF2α to a thromboxane (Tx) mimetic, U46,619, to determine relative pulmonary vasoconstrictive effects. We next determined if the vasoconstriction induced by both agonists would be reversed by 50 ppm of inhaled nitric oxide (NO). We also determined the degree of inhibition of U46,619 and of 8-epi-PGF2α by a Tx receptor antagonist, SQ 30,741. Anesthetized, ventilated piglets (18 ± 2 days, 3.7 ± 0.5 kg) were infused with randomly selected doses of U46,619 and of 8-epi-PGF2α to describe dose-response curves plotting pulmonary vascular resistance (PVRi) against dose. When a maximal dose was achieved, inhaled NO (50 ppm) was administered. Results for the calculated PVRi (mm Hg/l/min/kg) are as follows (mean ± SD): for U46,619, baseline value: 43 ± 10, peak dose: 165 ± 46, and peak dose with NO: 73 ± 33; for 8-epi-PGF2α, baseline value: 38 ± 9, peak dose: 138 ± 30, and peak dose with NO: 72 ± 25, and for both drugs, PVRi at peak dose was greater than at baseline (p < 0.001). PVRi at peak dose plus NO also remained elevated above baseline (p < 0.05; repeated measures ANOVA). The Tx receptor antagonist SQ 30,741 (1–10 mg/kg) inhibited U46,619-induced pulmonary vasoconstriction completely; however, the 1 mg/kg dose provided only 90% inhibition against 8-epi-PGF2α. We conclude that 8-epi-PGF2α can contribute to pulmonary vasoconstriction in young piglets in a dose-dependent reversible manner and that it acts primarily via pulmonary vascular Tx receptors.